{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:48Z","timestamp":1794007488837,"version":"4.8.0"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["RP\u20102017\u201008\u2010ST2\u2010006"],"award-info":[{"award-number":["RP\u20102017\u201008\u2010ST2\u2010006"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Brexpiprazole augmentation is an effective treatment strategy for antidepressant\u2010refractory depression, but its optimal dosage remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To find the optimal dosage of brexpiprazole as augmentation of other antidepressants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched multiple electronic databases (from inception to September 16th, 2021) to identify double\u2010blind, randomized placebo\u2010controlled fixed\u2010dose trials evaluating brexpiprazole augmentation therapy in adults (\u226518\u2009years old, both genders) with major depressive disorder not adequately responding to one or more antidepressant treatment. Our outcomes of interest at 8\u2009weeks (range 4\u201312\u2009weeks) were efficacy (treatment response defined as 50% or greater reduction in depression severity), tolerability (dropouts due to adverse effects) and acceptability (dropouts for any reason). We performed a random\u2010effects, one\u2010stage dose\u2010effect meta\u2010analysis with restricted cubic splines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six studies met the inclusion criteria, including 1671 participants in total. The dose\u2010efficacy curve showed an increase up to doses around 2\u00a0mg (odds ratio [OR] 1.52, 95% confidence interval [CI] 1.12\u20132.06) and then a decreasing trend through the higher licensed dose up to 3\u00a0mg (OR 1.40, 95% CI 0.95\u20132.08). The shape of the dose\u2010tolerability curve was comparable to that of the efficacy and the dose\u2010acceptability curve showed a monotonic increasing trend but both had wide confidence bands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>One to two milligrams of brexpiprazole as augmentation treatment may achieve an optimal balance between efficacy, tolerability, and acceptability in the acute treatment of antidepressant\u2010refractory depression. However, the small number of included studies limit the reliability of the results. Further research is required to validate the findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.13438","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T08:03:21Z","timestamp":1655539401000},"page":"416-422","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimal dose of brexpiprazole for augmentation therapy of antidepressant\u2010refractory depression: A systematic review and dose\u2010effect meta\u2010analysis"],"prefix":"10.1111","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-0220","authenticated-orcid":false,"given":"Yuki","family":"Furukawa","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry University of Tokyo Hospital  Tokyo Japan"},{"name":"Tokyo Musashino Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Oguro","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Obata","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Hamza","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine University of Bern  Bern Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo G.","family":"Ostinelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Oxford  Oxford UK"},{"name":"Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre  Oxford UK"},{"name":"Oxford Health NHS Foundation Trust, Warneford Hospital  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-4535","authenticated-orcid":false,"given":"Kiyoto","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry University of Tokyo Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20701"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20906"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.21040338"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1096-5"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70283-5"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy052"},{"key":"e_1_2_15_12_1","first-page":"CD010558","article-title":"Psychological therapies for treatment\u2010resistant depression in adults","volume":"2018","author":"Ijaz S","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.03.019"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716664885"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.17r11693"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13145"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30217-2"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16r10749"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.4313"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2020.1765748"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa033"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852915000954"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12180"},{"key":"e_1_2_15_24_1","unstructured":"Otsuka Pharmaceutical Co Ltd.Highlights of prescribinginformation for Rexulti.2020. [Cited 25 February2022]. Available from URL:https:\/\/www.otsuka-us.com\/sites\/g\/files\/qhldwo3916\/files\/media\/static\/Rexulti-PI.pdf)."},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz040"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000308"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1347"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.08.019"},{"key":"e_1_2_15_31_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"e_1_2_15_32_1","doi-asserted-by":"crossref","unstructured":"CrippaA OrsiniN.Multivariate Dose\u2010Response Meta\u2010Analysis: The Dosresmeta R Package.2016.https:\/\/doi.org\/10.18637\/jss.v072.c01","DOI":"10.18637\/jss.v072.c01"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280218773122"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2021.165"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09688"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09689"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.17m12058"},{"key":"e_1_2_15_39_1","unstructured":"NCT00797966.Study of the safety and efficacy of OPC\u201034712 as adjunctive therapy in the treatment of patients with major depressive disorder. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00797966."},{"key":"e_1_2_15_40_1","unstructured":"NCT01670279.Phase 1 study to assess the safety\/tolerability of brexpiprazole as adjunctive therapy in elderly subjects with major depressive disorder. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01670279."},{"key":"e_1_2_15_41_1","unstructured":"NCT01837797.Efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01837797."},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03021-9"},{"key":"e_1_2_15_43_1","unstructured":"NCT03697603.A study of brexpiprazole in patients with major depressive disorder. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03697603."},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv060"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2018.23"},{"key":"e_1_2_15_46_1","unstructured":"NCT03538691.A trial to evaluate the efficacy safety & tolerability of brexpiprazole in the maintenance treatment of adults with major depressive disorder. Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03538691."},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.4281"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.13438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pcn.13438","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.13438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T22:47:31Z","timestamp":1692744451000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.13438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/pcn.13438"],"URL":"https:\/\/doi.org\/10.1111\/pcn.13438","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"2022-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}